These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 20425392)
21. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. Diaz AE; Mesa RA Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894 [TBL] [Abstract][Full Text] [Related]
22. Momelotinib for the treatment of myelofibrosis with anemia. Tremblay D; Mesa R Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Verstovsek S Clin Cancer Res; 2010 Apr; 16(7):1988-96. PubMed ID: 20215535 [TBL] [Abstract][Full Text] [Related]
32. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis. El Fakih R; Popat U Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276 [TBL] [Abstract][Full Text] [Related]
33. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment. Sastow D; Mascarenhas J; Tremblay D Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248 [TBL] [Abstract][Full Text] [Related]
34. Rationale for combination therapy in myelofibrosis. Mascarenhas J Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730 [TBL] [Abstract][Full Text] [Related]
35. JAK2 inhibitors: A reality? A hope? Apostolidou E; Kantarjian HM; Verstovsek S Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S340-5. PubMed ID: 19778862 [TBL] [Abstract][Full Text] [Related]
36. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis]. Barba P; Fox ML; Blanco A; Valcárcel D Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663 [No Abstract] [Full Text] [Related]
37. State-of-the-Art Review on Myelofibrosis Therapies. Wang F; Qiu T; Wang H; Yang Q Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489 [TBL] [Abstract][Full Text] [Related]
38. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Winton EF; Kota V Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927 [TBL] [Abstract][Full Text] [Related]
39. Managing patients with myelofibrosis and low platelet counts. Al-Ali HK; Vannucchi AM Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535 [TBL] [Abstract][Full Text] [Related]